Eli Lilly and Company (LLY) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide), to meet supply shortages in response to high demand. These 2.5 mg and 5 mg single-dose vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity. A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is presently available in a single-dose pen (autoinjector). The vials should be eas ...

Investment Rating - The report assigns a "Hold" rating for the company with a target price of $959.49, indicating a potential upside of 0.9% from the current price of $950.53 [2][3]. Core Insights - The company reported a significant revenue increase of 36% year-over-year, reaching $11.3 billion in Q2 2024, with a net profit of $2.967 billion, reflecting a 56% increase [1]. - The strong performance is primarily driven by the robust sales of Tirzepatide, which saw a 71% quarter-over-quarter increase, contributing significantly to the metabolic segment's revenue growth of 50% [1][2]. - The company is expanding its production capacity for Tirzepatide, with expectations to increase capacity by 1.5 times in the second half of 2024 compared to the second half of 2023 [1]. Summary by Sections Financial Performance - Q2 2024 revenue was $11.3 billion, with a gross profit of $9.13 billion and a gross margin of 80.8% [1]. - R&D expenses were $2.71 billion, representing 24% of revenue, while marketing and administrative expenses were $2.12 billion, accounting for 18.7% of revenue [1]. - The company achieved a net profit margin of 26.3% with earnings per share of $3.28 [1]. Product Pipeline and Growth Drivers - The metabolic segment's revenue growth was significantly supported by Tirzepatide, with sales reaching $3.09 billion, and Zepbound sales increased by 140% to $1.24 billion [1][2]. - The oncology segment also showed strong growth, with sales increasing by 29%, driven by the CDK4/6 inhibitor Abemaciclib and the third-generation BTK inhibitor Pirtobrutinib [2]. - The autoimmune segment's revenue grew by 17%, with potential approval for Lebrikizumab in the U.S. expected to further boost growth [2]. Market Position and Future Outlook - The company is well-positioned in the pharmaceutical industry, with a market capitalization of $903.4 billion and a strong pipeline of products [3]. - The anticipated production ramp-up and new product approvals are expected to sustain growth momentum in the coming quarters [1][2].

Key TakeawaysHims & Hers Health shares declined Tuesday after Eli Lilly said it would be offering a lower-priced version of its popular Zepbound weight-loss treatment.Lilly explained that the new product would be sent directly to consumers.Hims & Hers recently began offering a copycat version of Novo Nordisk's Wegovy and Ozempic, and planned to have one for Zepbound in the near future. Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs ...

ROCKVILLE, Md., Aug. 27, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2024 class in AKF’s Corporate Membership Program as a Champion-level member. Boehringer Ingelheim and Lilly will help provide financial support for AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research. “AKF is pleased to continue partnering with Boehringer Ingelheim and Lilly in our efforts to help ...

Key TakeawaysEli Lilly is launching singe-use vials of its popular weight-loss drug Zepbound, which will be half the price of previous versions of the drug.The traditional injector pens are more difficult to produce, while the vials will allow customers to use any syringe to inject the medicine.The 2.5 mg and 5 mg vials will cost $399 and $549, respectively, for a four-week supply. Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the comp ...

By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . You can opt-out at any time by visiting our Preferences page or by clicking "unsubscribe" at the bottom of the email.Access your favorite topics in a personalized feed while you're on the go. download the appThanks for signing up! Go to newsletter preferencesSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewOne of the biggest weight-loss drugs on the market will ...

Eli Lilly is expanding the supply of its weight-loss drug and selling it for half the price of other drugs in the highly lucrative market.  Eli Lilly announced on Tuesday that it is now offering 2.5 mg and 5 mg single-dose vials of tirzepatide, sold under the brand name Zepbound, in response to growing demand. In its last fiscal quarter, the company's earnings surpassed Wall Street expectations due in large part because of the performance of Mounjaro and Zepbound, which have the same active ingredient but h ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare. The move also aims to expand the supply of Zepbound in the U.S. as demand skyrockets, and to ensure eligible patients are safely accessing the real treatment as cheaper cop ...

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesityINDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand. The single-dose vials are priced at a 50% or grea ...

Prior to an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap into stocks that are of high quality.In this regard, we ran a screener that yielded Norwegian Cruise Line Holdings Ltd. (NCLH) , Eli Lilly (LLY) , The Progressive (PGR) and Fortinet (FTNT) as the likely winners on the earnings beat potential.Why is a Positive Earnings Surprise Important?Historically, stocks of companies with ...